CA2658951A1 - Adult sertoli cells and uses thereof - Google Patents

Adult sertoli cells and uses thereof Download PDF

Info

Publication number
CA2658951A1
CA2658951A1 CA002658951A CA2658951A CA2658951A1 CA 2658951 A1 CA2658951 A1 CA 2658951A1 CA 002658951 A CA002658951 A CA 002658951A CA 2658951 A CA2658951 A CA 2658951A CA 2658951 A1 CA2658951 A1 CA 2658951A1
Authority
CA
Canada
Prior art keywords
cells
sertoli cells
adult
composition
neonatal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002658951A
Other languages
English (en)
French (fr)
Inventor
David J. White
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sertocell Biotechnology US Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2658951A1 publication Critical patent/CA2658951A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
CA002658951A 2006-07-28 2007-07-27 Adult sertoli cells and uses thereof Abandoned CA2658951A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82076006P 2006-07-28 2006-07-28
US60/820,760 2006-07-28
PCT/US2007/074623 WO2008014470A2 (en) 2006-07-28 2007-07-27 Adult sertoli cells and uses thereof

Publications (1)

Publication Number Publication Date
CA2658951A1 true CA2658951A1 (en) 2008-01-31

Family

ID=38982397

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002658951A Abandoned CA2658951A1 (en) 2006-07-28 2007-07-27 Adult sertoli cells and uses thereof

Country Status (6)

Country Link
US (1) US20090191167A1 (https=)
EP (1) EP2046351A2 (https=)
JP (2) JP2010500871A (https=)
AU (1) AU2007278850B2 (https=)
CA (1) CA2658951A1 (https=)
WO (1) WO2008014470A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050118145A1 (en) * 2003-07-03 2005-06-02 Jannette Dufour Compositions containing sertoli cells and myoid cells and use thereof in cellular transplants
EA025142B1 (ru) 2009-08-28 2016-11-30 Сернова Корпорэйнш Способ и устройство для клеточной трансплантации
JP6293569B2 (ja) * 2014-04-25 2018-03-14 愛三工業株式会社 液面検出装置

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545223A (en) * 1990-10-31 1996-08-13 Baxter International, Inc. Ported tissue implant systems and methods of using same
US5958404A (en) * 1994-04-13 1999-09-28 Research Corporation Technologies, Inc. Treatment methods for disease using co-localized cells and Sertoli cells obtained from a cell line
US5849285A (en) * 1994-04-13 1998-12-15 Research Corporation Technologies, Inc. Autoimmune disease treatment with sertoli cells and in vitro co-culture of mammal cells with sertoli cells
DE69525151T2 (de) * 1994-04-13 2002-08-14 Research Corp. Technologies, Inc. Methoden zur krankheitsbehandlung unter verwendung von sertoli-zellen und allotransplantat oder xenotransplantat
US5759536A (en) * 1994-05-27 1998-06-02 University Technology Corporation Use of fas ligand to supress T-lymphocyte-mediated immune responses
MX9706062A (es) * 1995-02-08 1997-10-31 Yamanouchi Europ Bv FORMAS DE DOSIFICACION ORAL CONTENIENDO UN ANTIBIOTICO DE beta -LACTAMA.
US5830460A (en) * 1995-03-13 1998-11-03 University Of South Florida Sertoli cells as transplantation facilitator for cell transplantation
US20040086494A1 (en) * 1996-10-07 2004-05-06 John Constance Mary Immune privileged cells for delivery of proteins and peptides
US20020065212A1 (en) * 1996-11-08 2002-05-30 Selawry Helena P. Methods of treating disease using sertoli cells and allografts or xenografts
ES2338076T3 (es) * 1998-11-06 2010-05-03 Sertoli Technologies, Inc. Produccion de un factor biologico y creacion de un entorno inmunologicamente privilegiado usando celulas de sertoli alteradas geneticamente.
CA2355675C (en) * 1998-12-15 2006-07-04 Universidad Nacional Autonoma De Mexico Process and device for facilitating the implantation of biological material
US6303355B1 (en) * 1999-03-22 2001-10-16 Duke University Method of culturing, cryopreserving and encapsulating pancreatic islet cells
US6365385B1 (en) * 1999-03-22 2002-04-02 Duke University Methods of culturing and encapsulating pancreatic islet cells
ES2272482T3 (es) * 2000-01-20 2007-05-01 Diabcell Pty Limited Preparacion y xenotransplante de islotes porcinos.
US6790441B1 (en) * 2000-06-13 2004-09-14 University Of South Florida Sertoli cells as biochambers
US20040014212A1 (en) * 2000-10-17 2004-01-22 Elliott Robert Bartlett Preparation and xenotransplantation or porcine islets
KR20030096381A (ko) * 2001-05-11 2003-12-24 오쏘-맥네일 파머슈티칼 인코퍼레이티드 동물에 사용하기 위한 면역 조절장치
CN1791670A (zh) * 2003-06-24 2006-06-21 戴伯塞尔有限公司 用于异种移植的用猪支持细胞培养的猪胰岛
US20050118145A1 (en) * 2003-07-03 2005-06-02 Jannette Dufour Compositions containing sertoli cells and myoid cells and use thereof in cellular transplants
US20060182722A1 (en) * 2005-02-11 2006-08-17 Hering Bernhard J Methods and materials for isolating isogenic islet cells

Also Published As

Publication number Publication date
AU2007278850B2 (en) 2013-06-06
JP2010500871A (ja) 2010-01-14
EP2046351A2 (en) 2009-04-15
WO2008014470A3 (en) 2008-09-18
US20090191167A1 (en) 2009-07-30
AU2007278850A1 (en) 2008-01-31
WO2008014470A2 (en) 2008-01-31
JP2014074041A (ja) 2014-04-24

Similar Documents

Publication Publication Date Title
Mital et al. Immunoprotective sertoli cells: making allogeneic and xenogeneic transplantation feasible
Dufour et al. Long‐term survival of neonatal porcine Sertoli cells in non‐immunosuppressed rats
Hemendinger et al. Identification of a specific Sertoli cell marker, Sox9, for use in transplantation
Haque et al. Combination strategy of multi-layered surface camouflage using hyperbranched polyethylene glycol and immunosuppressive drugs for the prevention of immune reactions against transplanted porcine islets
US20030096016A1 (en) Methods of kidney transplantation utilizing developing nephric tissue
RS64754B1 (sr) Fasl-izrađeni biomaterijali sa imunomodularnom funkcijom
Halberstadt et al. Use of Sertoli cell transplants to provide local immunoprotection for tissue grafts
AU2007278850B2 (en) Adult sertoli cells and uses thereof
EP2216033B1 (en) Methods of treating disease by transplantation of allogeneic or xenogeneic organs or tissues
US20090162331A1 (en) Compositions containing sertoli cells and myoid cells and use thereof in cellular transplants
AU2013222011A1 (en) Adult Sertoli Cells and Uses Thereof
Anggelia et al. Single injection of tacrolimus-loaded thermosensitive hydrogel improves outcomes in vascularized composite allotransplantation
AU2011224113B2 (en) Compositions containing Sertoli cells and myoid cells and use thereof in cellular transplants
US20240245762A1 (en) Methods and platforms for promoting antigen-specific tolerance in the treatment of type 1 diabetes and graft rejection and compositions relating thereto
Copeman Inhibition of Antibody Responses to Cellular Xenotransplants
Dean Transplantation of fetal pig islet-like cell clusters as therapy for diabetes
ES2445523T3 (es) Procedimientos de tratamiento de enfermedad por trasplante de órganos o tejidos alógenos o xenógenos
JP2022126281A (ja) 免疫抑制剤なしで拒絶制御を可能にする脂肪由来間葉系幹細胞の誘導方法ならびに移植方法
Bayrack Evaluation of the Protection Induced by a Monotherapy of Anti-LFA-1 Monoclonal Antibody and Co-transplantation of Neonatal Porcine Islets with Sertoli Cells
Vaithilingam Microencapsulated human islets as a therapy for type 1 diabetes
Mallett A systematic approach to the encapsulation of islets for transplantation.
ZA200507056B (en) Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20161208